Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GRN | P28799 | 1/20 | 0.36 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.36 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.30 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27584232 | 0.84 | GRN (0.47) | MAPK1GRNSORT1BACE1KEAP1 | |
| SCHEMBL28528204 | 0.81 | MAPK1 (0.41) | MAPK1GRNSORT1BACE1KDM4E | |
| SCHEMBL1361481 | 0.81 | MAPK1 (0.41) | MAPK1GRNSORT1BACE1KDM4E | |
| SCHEMBL14211341 | 0.78 | GRN (0.44) | MAPK1GRNSORT1BACE1KDM4E | |
| SCHEMBL14533530 | 0.78 | GRN (0.44) | MAPK1GRNSORT1BACE1KDM4E | |
| SCHEMBL16508862 | 0.75 | MAPK1 (0.48) | MAPK1GRNSORT1BACE1CA1 | |
| SCHEMBL12171679 | 0.75 | MAPK1 (0.48) | MAPK1GRNSORT1BACE1CA1 | |
| SCHEMBL23805193 | 0.74 | CTSK (0.46) | CA1CA2 | |
| SCHEMBL2158515 | 0.74 | CTSK (0.46) | CA1CA2 | |
| SCHEMBL8372342 | 0.74 | CTSK (0.46) | CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1400515-B1 | CYCLIC DIAMINE COMPOUND HAVING FIVE-MEMBERED CYCLIC GROUP | KOWA CO (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | IDENIX PHARMACEUTICALS, INC. (US) | 2009-02-19 | — | — | US | disclosed |
| EP-1400515-A1 | CYCLIC DIAMINE COMPOUND HAVING FIVE-MEMBERED CYCLIC GROUP | Kowa Co., Ltd. (JP) | 2004-03-24 | — | — | EP | disclosed |
| US-6472386-B1 | Cyclic diamine compound with 5-membered ring groups | KOWA CO., LTD. (JP) | 2002-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047244-A1 | MACROCYCLIC SERINE PROTEASE INHIBITORS I | SERPINB1, SPINT2, PRSS1 | MAPK1 2565/4885GRN 1136/4885SORT1 1885/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.